GLP-1, GIP & Inflammation: What These Medications Really Do and What They Dont Joshua Silva, MD Dec 5, 2025 7 min read Updated: Jan 27 Medically authored by Joshua Silva, MD | Evidence-Based Weight Loss at Potere Health MD Quick Answer GLP-1 and GLP-1/GIP medications (such as semaglutide and tirzepatide ) can lower metabolic inflammation by improving insulin resistance, reducing visceral fat, and lowering inflammatory biomarkers such as C-reactive protein (CRP) ., They can also improve cardiometabolic risk markers (e.g., blood pressure) and, for tirzepatide, can improve atherogenic lipoprotein measures including apoB and triglyceride-rich lipoproteins in clinical research settings., They do not treat autoimmune diseases or fibromyalgia directly

How will Cagri-Sema stack up against Tirzepatide and later Retatrutide #obesity #weightloss #T2D novonordisk.com/content/dam/nn How will Cagri-Sema stack up against Tirzepatide and later Retatrutide #obesity #weightloss #T2D novonordisk.com/content/dam/nn I feel like the question is, does amylin agonism or glucagon agonism produce better cardiometabolic, renal and hepatic outcomes
The American Heart Association's 2023 AF anticoagulation guidance lists metabolic syndrome and obesity-related NAFLD as independent factors that alter warfarin sensitivity, which supports heightened vigilance in exactly the patient population receiving triple agonists
Neoadjuvant Setting: Specifically, caution is advised for patients using GLP-1 RAs during neoadjuvant regimens like the phase 3 KEYNOTE-522 trial